Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

The hope is that a new generation of non-opioid analgesics will become available to treat both acute and chronic pain and have a reduced risk of addiction. In 2023, more than 100,000 lives were ...

Leaders with Project Opioid, a non-profit established after the opioid epidemic was declared a public health emergency in ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Mexico has handled the cartels so poorly that it broke international law. It is obligated to prevent the harm cartels are ...

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...

The one-size-fits-all approach to pain management should be a thing of the past. But we’re still not there yet.